GEN Exclusives

More »

GEN News Highlights

More »
Jul 27, 2010

The Leukemia & Lymphoma Society to Provide Shape Pharmaceuticals with $3.3M

  • The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals entered into a partnership to advance the firm’s topical treatment for cutaneous T-cell lymphoma (CTCL) into clinical development. LLS will provide up to $3.3 million through its Therapy Acceleration Program (TAP) to support the remaining preclinical studies needed for an IND and a Phase Ib study.

    The compound, SHP-141, was discovered by LLS-funded researcher James Bradner, M.D., of Dana-Farber Cancer Institute, and Ralph Mazitschek, Ph.D., of Massachusetts General Hospital. Drs. Bradner and Mazitschek founded Shape in 2008 with funding and management from HealthCare Ventures.

    SHP-141 is a small molecule, histone deacetylase inhibitor designed to result in activity directly on the skin without systemic exposure. By limiting systemic toxicity, SHP-141 has potential for application during the protracted early stages of CTCL in addition to during late-stage disease as part of a combination therapy. The clinical trial is expected to enroll patients in early 2011.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?